Delving into the Latest Updates on Tacrolimus with Synapse

Overview

Basic Info

Drug Type

Molecular glue

Synonyms

Inhaled tacrolimus, mdc-GRT, Nano-Tacrolimus

+ [61]

Target

CaN

Action

inhibitors

Mechanism

CaN inhibitors(Calcineurin inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [11]

Active Indication

Vernal KeratoconjunctivitisLung Diseases, InterstitialSmall intestine transplantation rejection+ [80]

Inactive Indication

Acute Chest SyndromeAcute Graft Versus Host DiseaseAcute myeloid leukaemia with 11q23 abnormality+ [124]

Originator Organization

Astellas Pharma, Inc.

Active Organization

Astellas Pharma, Inc.

Fred Hutchinson Cancer Research CenterAstellas Pharma Europe Ltd.

+ [26]

Inactive Organization

Barbara Ann Karmanos Cancer Institute

The Children's Oncology Group Foundation, Inc.Astellas Pharma Canada, Inc.

+ [19]

License Organization

Aequus Pharmaceuticals, Inc.

Veloxis Pharmaceuticals A/S

Taiba Pharma

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (08 Apr 1994),

Graft Rejection

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC44H71NO13

InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N

CAS Registry109581-93-3

This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis. A total of 66 participants will be randomized (1:1) to receive either Crisaborole or Tacrolimus, applied twice daily to affected areas for 28 days. Primary endpoint is proportion of participants achieving Investigator's Static Global Assessment (ISGA) success (clear/almost clear with ≥2-point improvement from baseline) at Day 28. Safety assessments include adverse events and local application site reactions.

Start Date01 Jun 2026

Sponsor / Collaborator-

NCT07249346

/ RecruitingPhase 2IIT

An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

Start Date01 Jun 2026

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

NCT06996119

/ Not yet recruitingPhase 1IIT

Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor [peripheral blood stem cell] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.

Start Date25 May 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Tacrolimus

Login to view more data

100 Translational Medicine associated with Tacrolimus

Login to view more data

100 Patents (Medical) associated with Tacrolimus

Login to view more data

22,329

Literatures (Medical) associated with Tacrolimus

01 Apr 2026·JOURNAL OF ETHNOPHARMACOLOGY

Integrated metabolomics and proteomics analysis elucidated the therapeutic effect of Huangkui Capsule on tacrolimus-induced chronic nephrotoxicity in rats

Article

Author: Zhang, Feng ; Tang, Tingting ; Han, Jun ; Tao, Xia ; Yang, Liyuan ; Pang, Tao ; Li, Jingjing ; Yang, Hong ; He, Yuqiong ; Chen, Wansheng ; Wang, Yejian

ETHNOPHARMACOLOGICAL RELEVANCE:

Huangkui capsule (HK) has demonstrated significant efficacy in managing chronic kidney disease. Previous studies have shown that HK can alleviate kidney damage; however, the therapeutic effects of HK on tacrolimus-induced chronic nephrotoxicity (TCN) and the underlying molecular mechanisms remain unclear.

AIM OF THE STUDY:

To evaluate the effectiveness of HK in alleviating TCN and to explore its underlying mechanisms of action.

MATERIALS AND METHODS:

The therapeutic efficacy of HK was evaluated on the TCN rat model using biochemical indices and histopathological examinations. Integrated kidney metabolomic and proteomic profiling were analyzed to reveal the TCN related distinct dysregulated pathways and potential targets, and provide mechanistic insights into the relationship between targets and active components from HK. Molecular docking and Western blot analyses were further used for the validation.

RESULTS:

TCN rats showed increased proteinuria and a deterioration of kidney function, accompanied by increased inflammation and oxidative stress, whereas HK improved kidney damage in a dose-dependent manner. Integrated metabolomics and proteomics analyses showed that HK inhibited TCN by the restoration of glutathione metabolism and upregulation of Gclc, Gclm, Slc7a11, Slc3a2, and Gpx4, and revealed a specific regulatory mechanism of ferroptosis by the constructed "protein-pathway-metabolite" network analysis. Mechanistically, tacrolimus intervention increased intracellular Fe²⁺ levels, suppressed system xCT activity by downregulation of Slc7a11 and Slc3a2, and reduced Gpx4 levels, thereby increasing susceptibility to ferroptosis. Tamarixetin and quercetin-7-O-β-glucuronide from HK could reverse these effects, restoring expression levels of Slc7a11, Slc3a2, and Gpx4, exhibiting effects comparable to Fer-1.

CONCLUSIONS:

HK attenuated TCN through suppression of ferroptosis, as demonstrated by integrated metabolomic and proteomic analyses. This protective effect was mediated by its bioactive components, specifically quercetin, tamarixetin, and quercetin-7-O-β-glucuronide, which enhanced GSH synthesis and inhibited lipid peroxidation via upregulation of Slc7a11/Slc3a2 system.

01 Apr 2026·DEN open

Severe Gastroduodenitis Associated With Ulcerative Colitis After Total Colectomy Successfully Treated With Endoscopic Hemostasis and Oral Tacrolimus

Article

Author: Fujiwara, Yasuhiro ; Tanaka, Fumio ; Fujimoto, Koji ; Kobayashi, Yumie ; Nakata, Rieko ; Hosomi, Shuhei ; Nishida, Yu

ABSTRACT:

Herein, we report a rare case of gastroduodenitis associated with ulcerative colitis (UC). A 42‐year‐old man was diagnosed with UC 1 year prior to admission to our hospital. The patient underwent a 3‐stage total colectomy and ileal pouch‐anal anastomosis for severe UC. Two months after the second surgery, the patient was admitted to our hospital with nausea, appetite loss, abdominal pain, and frequent bloody diarrhea. Blood analysis showed an increase in white blood cell count and C‐reactive protein levels. Esophagogastroduodenoscopy (EGD) revealed diffuse UC‐like inflammation from the stomach to the duodenum and ulcers in the descending and horizontal regions of the duodenum. Pouchoscopy revealed ulcers and friable mucosa within the pouch. The patient was diagnosed with gastroduodenitis associated with UC (GDUC) and diversion pouchitis based on endoscopic and pathological findings. Inflammation in the GDUC was resistant to oral crushed mesalazine and prednisolone (60 mg/day) infusion, resulting in arterial bleeding from the duodenal ulcer and bloody stool in the stoma. Endoscopic hemostasis was performed for the duodenal ulcer. Oral tacrolimus was initiated because the inflammation was steroid‐resistant. Approximately 2 weeks after the initiation of tacrolimus, abdominal symptoms, including bloody diarrhea, disappeared, and EGD showed improvement in the GDUC.

01 Mar 2026·INTERNATIONAL IMMUNOPHARMACOLOGY

Comparative efficacy of mesenchymal stromal cells versus multi-target therapy in systemic lupus erythematosus

Article

Author: Sun, Lingyun ; Yue, Rui ; Wang, Jia ; Jing, Lijuan ; Li, Wenchao ; Li, Hui ; Shen, Wei ; Yan, Han

Systemic lupus erythematosus (SLE) treatment requires balancing rapid autoimmunity control with long-term organ repair. Mesenchymal stromal cells (MSCs) and multi-target pharmacotherapy represent fundamentally different therapeutic strategies. MSCs exert context-dependent immunomodulation, whereas the latter relies on broad immunosuppression. This contrast makes direct comparison essential to guide therapy decisions. Here, we conducted a head-to-head evaluation of these two strategies in a lupus murine model. Lupus mice received either umbilical cord-derived MSCs or TMP (tacrolimus, mycophenolate mofetil and prednisone) over an 8-week period. Both treatments significantly alleviated core lupus symptoms, including enlarged spleen/lymph nodes and excessive antibody production. However, MSCs showed greater efficacy in suppressing pathogenic autoantibodies, repairing podocyte damage, and increasing protective regulatory T cells in the kidney and peripheral tissues. TMP more effectively reduced peripheral circulating immune cells. These findings highlight the complementary therapeutic profiles of MSCs and multi-target pharmacotherapy in SLE, providing a critical rationale for personalized treatment stratification.

282

News (Medical) associated with Tacrolimus

26 Jan 2026

·www.novaliq.com

Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-Infectious Anterior Uveitis

Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis Heidelberg, Germany and Cambridge, MA, USA, January 26, 2026 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). Anterior uveitis is an inflammation of the inner eye including the iris and ciliary body, that typically causes a red, painful, light‑sensitive eye and can lead to vision loss if not treated promptly. NIAU represents 67-90% of uveitis cases in the developed world.1 To treat uveitis a drug must reach the uveal tract inside the eye. Current treatment choices are limited to corticosteroid eye drops and, if insufficient or the inflammation is more severe, periocular or intraocular corticosteroid injections and systemic immunosuppressive agents are applied, all of which are known to be associated with complications.2 Oral tacrolimus was shown effective but has low bioavailability in eye tissues and systemic side effects limit its use. Delivery of topical tacrolimus to the tissues inside the eye has not been shown yet. “The IND clearance of the EYETAC study is a major milestone on our strategic expansion to retina and diseases of the inner-eye using targeted topical delivery of EyeSol® based drugs,” said Dr. Christian Roesky, Chief Executive Officer Novaliq. “A steroid-free eye drop that effectively controls intraocular inflammation, without associated side effects, is an unmet medical need currently in patients with NIAU and that could be addressed with NOV05. Furthermore, the study aims to demonstrate a general proof of delivery of active ingredients to the back of the eye tissues using EyeSol®, which would allow us to develop multiple topical EyeSol® therapies for retina diseases.” EYETAC is a phase 2, randomized, double-masked clinical trial (NCT #07285070) conducted at clinical centers in the United States of America, in patients with active NIAU, evaluating two concentrations of tacrolimus, and is expected to begin in the first quarter of 2026. The study aims to evaluate the safety and tolerability of NOV05 and to assess the potential dose-dependent clinical anti-inflammatory effect. The clinical study is based on the prior ocular pharmacokinetics findings demonstrating delivery of tacrolimus to ocular tissues after topical application in two species3, the demonstration of pharmacological effect in two independent animal models of experimental uveitis4, and the successful toxicology study4. About Novaliq Novaliq is a private biopharmaceutical company focusing on the development of first- and best-in-class ocular therapeutics. Novaliq developed EyeSol®, a novel drug category of water-free topical eye medicines. Two FDA-approved EyeSol® medicinal products for dry eye disease – Miebo® and Vevye® – are on the market in the US and have transformed patient care. The Novaliq R&D pipeline provides multiple development opportunities in ophthalmology and retina therapies. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term single shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com. Recommended Readings Joltikov KA, Lobo-Chan AM. Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review. Front Med (Lausanne). 2021 Sep 10;8:695904. Wu X, Tao M, Zhu L, Zhang T, Zhang M. Pathogenesis and current therapies for non-infectious uveitis. Clin Exp Med. 2023 Aug;23(4):1089-1106 Kroesser S, Korward J, Sheppard JD, Perez VP. Ocular distribution of Tacrolimus after topical administration as EyeSol formulations in rabbits and dogs. Investigative Ophthalmology & Visual Science June 2025, Vol.66, 652 and ARVO 2025 poster Novaliq data on file. Any product/brand names and/or logos are trademarks of their respective owners. © 2026 Novaliq GmbH, Heidelberg, Germany. All rights reserved.

Phase 2IND

26 Jan 2026

·retinalphysician.com

FDA Clears Novaliq Uveitis Program

Novaliq announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug application for NOV05, a topical tacrolimus ophthalmic solution formulated in the company’s EyeSol drug delivery platform. The clearance allows initiation of the phase 2 EYETAC clinical trial in patients with noninfectious anterior uveitis. NOV05 is Novaliq’s first IND cleared for an inner-eye indication. The investigational therapy is designed as a steroid-free topical anti-inflammatory treatment intended to deliver tacrolimus to uveal tissues. Although oral tacrolimus has demonstrated efficacy, its use is limited by systemic adverse effects and poor ocular bioavailability. Effective topical delivery of tacrolimus to intraocular tissues has not yet been established. The EYETAC trial is a randomized, double-masked study to be conducted at US clinical centers and is expected to begin in the first quarter of 2026. The study will evaluate 2 concentrations of NOV05, focusing on safety, tolerability, and potential dose-dependent anti-inflammatory effects. The program is supported by prior pharmacokinetic, preclinical efficacy, and toxicology studies, the company said in a press release. RP

IND

09 Jan 2026

·www.fiercepharma.com

Orca rides $250M funding wave toward cancer cell therapy launch

Orca will use the money to scale up for commercialization. Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.California-based Orca filed for FDA approval of its allogeneic T-cell immunotherapy Orca-T last year. Using purified donor regulatory T cells, Orca-T is designed to prevent graft-versus-host disease (GvHD) with less immunosuppression than is required for conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). The FDA is set to decide by April 6 whether to approve the drug candidate as a treatment for hematological malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.Orca has been gearing up for commercialization in anticipation of approval. Friday, the biotech said it has raised $250 million across two rounds, including a series F financing that closed last month, and that it secured up to $100 million in credit from Silicon Valley Bank. An Orca spokesperson said the capital raised was comparable between the two rounds. The previously undisclosed series E round completed in 2024, the spokesperson said.Orca disclosed its $192 million series D round in a Securities and Exchange Commission filing in 2020, but no entries appear for the two subsequent rounds. Orca will use the money to scale up for commercialization, including by adding manufacturing capacity on the East Coast to complement its existing operations in California. The biotech put Steve Gavel in charge of commercial activities in June. However, Gavel, who worked on the Carvykti launch at Legend Biotech, lasted just a few months at Orca before joining Cabaletta Bio in October. Mike Hirschmann, who joined Orca as senior vice president of U.S. commercial, stepped up to the chief commercial officer role when Gavel departed. Like Gavel, Hirschmann worked at Legend before joining Orca. If Orca-T wins approval, the commercial team will need to persuade physicians to use the product over existing methods for preventing GvHD. A phase 3 trial linked Orca-T to significantly better survival free from moderate-to-severe chronic GvHD in patients with hematological malignancies than conventional alloHSCT with tacrolimus and methotrexate. The combination of tacrolimus and methotrexate is one way physicians try to prevent GvHD in these patients.Other trials found that antithymocyte globulin (ATG) and cyclophosphamide (PTCy) are better at preventing GvHD than tacrolimus and methotrexate. A retrospective analysis of patients in a phase 1b trial of Orca-T yielded evidence that the therapy may have advantages over PTCy. Yet the researchers who wrote up Orca’s phase 3 data said a randomized trial versus PTCy or ATG may be needed to reach a definitive conclusion.

Clinical ResultImmunotherapyCell TherapyPhase 3Phase 1

100 Deals associated with Tacrolimus

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08556	Tacrolimus	L04AD02 D11AH01	DB00864

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Vernal Keratoconjunctivitis	South Korea	Taejoon Pharm Co., Ltd.	11 Jul 2019
Lung Diseases, Interstitial	Japan	Astellas Pharma, Inc.	14 Jun 2013
Small intestine transplantation rejection	Japan	Astellas Pharma, Inc.	26 Jul 2011
Colitis, Ulcerative	Japan	Astellas Pharma, Inc.	07 Jul 2009
Mucositis	Japan	Senju Pharmaceutical Co., Ltd.	25 Jan 2008
Allograft Rejection	European Union	Astellas Pharma Europe BV	23 Apr 2007
Allograft Rejection	Iceland	Astellas Pharma Europe BV	23 Apr 2007
Allograft Rejection	Liechtenstein	Astellas Pharma Europe BV	23 Apr 2007
Allograft Rejection	Norway	Astellas Pharma Europe BV	23 Apr 2007
Liver transplant rejection	European Union	Astellas Pharma Europe BV	23 Apr 2007
Liver transplant rejection	Iceland	Astellas Pharma Europe BV	23 Apr 2007
Liver transplant rejection	Liechtenstein	Astellas Pharma Europe BV	23 Apr 2007
Liver transplant rejection	Norway	Astellas Pharma Europe BV	23 Apr 2007
Lupus Nephritis	Japan	Astellas Pharma, Inc.	26 Jan 2007
Rejection of pancreas transplant	Japan	Astellas Pharma, Inc.	19 Jan 2005
Lung transplant rejection	Japan	Astellas Pharma, Inc.	31 Jan 2003
Cardiac transplant rejection	Japan	Astellas Pharma, Inc.	20 Jun 2001
Myasthenia Gravis	Japan	Astellas Pharma, Inc.	20 Sep 2000
Dermatitis, Atopic	Japan	Maruho Co., Ltd.	16 Jun 1999
Bone marrow transplant rejection	Japan	Astellas Pharma, Inc.	30 Apr 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal and pancreas transplant rejection	Phase 3	United States	Veloxis Pharmaceuticals A/S	27 Feb 2019
Kidney Failure, Chronic	Phase 3	United States	Northwestern University	05 Sep 2017
Tremor	Phase 3	United States	Veloxis Pharmaceuticals A/S	01 Dec 2011
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
Hodgkin's Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
Indolent B-Cell Non-Hodgkin Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
Indolent Non-Hodgkin Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
Mantle-Cell Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
Non-Hodgkin Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009
T-Cell Lymphoma	Phase 3	United States	Dana-Farber Cancer Institute, Inc.	01 Jun 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05115630 (CTgov)	Phase 2	Myeloid Tumor \| Acute Myeloid Leukemia \| Chronic phase chronic myeloid leukemia ... View more	24	TBI+Fludarabine+Melphalan	hmiodntlvr = yudwuxyqft zqffipcxms (jiqguosejd, qdxpftkbfd - yodwwgispv) View more	-	19 Dec 2025
NCT03979365 (SIMPLE, CTgov)	Phase 4	Renal transplant rejection	261	Tacrolimus twice daily (Tacrolimus Twice-daily)	hdljliowez(yuudacsden) = izvfoiypjg uiahqyzaia (qplcgaevzc, 14.053) View more	-	18 Dec 2025
				Envarsus XR (Envarsus XR)	hdljliowez(yuudacsden) = tqasdnnner uiahqyzaia (qplcgaevzc, 14.846) View more
NCT01349101 (CTgov)	Phase 2	Hematologic Neoplasms \| Chronic Myelomonocytic Leukemia \| acute leukemia	78	Hematopoietic stem cell transplantation+Cyclophosphamide+Tacrolimus+mycophenolate mofetil (Myeloablative HSCT)	qqwoaggtim = chothsauts hhnlepeqik (luurxdqlxg, ooxemxroyc - sldcjkeeeo) View more	-	15 Dec 2025
				Hematopoietic stem cell transplantation+Fludarabine+Busulfan+Cyclophosphamide+Tacrolimus+mycophenolate mofetil (Reduced Intensity HSCT)	qqwoaggtim = pavjgmidao hhnlepeqik (luurxdqlxg, xbixqsuxhc - hekabfjgvg) View more
ASH2025	Not Applicable	Hematopoietic stem cell transplantation	277	tacrolimus (Shortened IS duration(<120 days))	gntsgjgjlh(bkoqialbtt) = vixhosppvg zwflgaekck (iioueaeqyx ) View more	Positive	06 Dec 2025
				tacrolimus (Traditional IS duration(≥120 days))	gntsgjgjlh(bkoqialbtt) = kvssitswsl zwflgaekck (iioueaeqyx ) View more
NCT04048161 (Pubmed \| JAMA Pediatr)	Phase 4	Nephrotic Syndrome	270	Tacrolimus	kpfpuoekfg(pabffccrko): HR = 2.86 (95% CI, 1.79 - 4.76)	Positive	01 Jul 2025
				Mycophenolate Mofetil
NCT04530487 (CTgov)	Phase 2	Refractory Malignant Solid Neoplasm \| Relapsed Solid Neoplasm \| Neuroblastoma recurrent ... View more	1	ATG+cyclosporine+etoposide+mephalan+tacrolimus+MMF+thiotepa	vnetmonlgk(ourlsppfmu) = lqudiovrmo vxecapwmjn (ejcdnrhcsb, avtyinwicq - ccchlsbiif) View more	-	29 Jun 2025
NCT02711202 (CTgov)	Not Applicable	Neoplasms	20	Remicade+Tacrolimus+Sirolimus+MabCampath, (Sirolimus)	gaiktgsgea = jizczlfyud fihxzivpbd (jmfhtopmfy, wzqvmwvugv - efzxrtriwa) View more	-	04 Jun 2025
				Remicade+Tacrolimus+MabCampath, (Tacrolimus)	gaiktgsgea = uguxejukii fihxzivpbd (jmfhtopmfy, ewtskbwhoc - cuttpzpldr) View more
NCT03461445 (CTgov)	Phase 4	Drug intoxication \| Neurotoxicity Syndromes \| Toxicity ... View more	64	IR Tacrolimus (Immediate Release Tacrolimus)	jmtqiyytza(zbdyuscrkc) = gzzqufvajh gotwtdcvmj (fazpvxiwde, 2.1) View more	-	08 Apr 2025
				Envarsus (Envarsus)	jmtqiyytza(zbdyuscrkc) = tkrkzvzrii gotwtdcvmj (fazpvxiwde, 2.9) View more
NCT02566304 (CTgov)	Phase 2	Refractory cytopenia with multilineage dysplasia and ringed sideroblasts \| Anemia, Refractory, With Excess of Blasts \| Relapsing acute myeloid leukemia ... View more	35	Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil	wmrvoktbqo = cgloytbfyy teetiaxint (pwbnogqydj, brpncxodcz - rotlznunqm) View more	-	20 Mar 2025
NCT01701986 (CTgov)	Phase 1/2	Refractory Hodgkin Lymphoma \| Hematopoietic stem cell transplantation \| B-cell lymphoma refractory ... View more	64	Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 1_475mgm2)	zyuaijbipn = bsebeyvlue mcohikgyyl (ybwbektnad, woignpxupk - vkebyexkil) View more	-	28 Feb 2025
				Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 2_675mgm2)	zyuaijbipn = ktvnwqsggt mcohikgyyl (ybwbektnad, kwgwnesslp - igbpxlhfij) View more